Abstract
During the past 10 years plasma high-density lipoprotein (HDL) cholesterol concentration has emerged as a major risk factor for coronary heart disease (CHD) in several westernized societies. The association between HDL and CHD has been found in both sexes, is independent of other lipoproteins, and is at least as strong as that between CHD and low-density lipoprotein (LDL) concentration. Angiographic and autopsy studies have indicated that the severity of coronary atherosclerosis is also a negative function of HDL. The epidemiology of HDL in relation to CHD has recently been reviewed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arntzenius AC (1986) Diet, lipoproteins and the progression of coronary atherosclerosis. Drugs 31 (Suppl 1): 61–65
Assmann G, Schulte H, Oberwittler W, Hauss W (1986) New aspects in the prediction of coronary heart disease: the PROCAM study. In: Fidge NH, Nestel PJ (eds) Atherosclerosis VII. Elsevier, Amsterdam, p 19
Bell GD, Bradshaw JP, Burgess A, et al. (1980) Elevation of serum HDL cholesterol by Rowachol, a proprietary mixture of six pure monoterpenes. Atherosclerosis 36:47–54
Benko S, Macher A, Szarvas F, Tiboldi T (1961) Effect of essential oils on atherosclerosis of cholesterol-fed rabbits. Nature (London) 190:731–732
Castelli WP, Anderson K (1986) A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham study. Am J Med 80(2A): 23–32
Duffìeld RGM, Lewis B, Miller NE et al. (1983) Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomized controlled trial. Lancet ii:639–642
Fears R, Esmail A, Walker P, Rush WR, Ferres H (1984) Hyperalphalipoproteinaemic activity of BRL26314 — II. Inhibition of atherosclerosis in rabbits. Biochem Pharmacol 33:219–228
Fredrickson DS, Levy RI (1972) Familial hyperlipoproteinemia. In: Stanbury JB, Wyngaarden JB, Fredrickson DS (eds) The metabolic basis of inherited disease. McGraw-Hill, New York, p 545
Goldbourt U, Medalie JH (1979) High density lipoprotein cholesterol and incidence of coronary heart disease — the Israeli ischemic heart disease study. Am J Epidemiol 109:296–308
Gordon T, Castelli WP, Hjortland MC et al. (1977) HDL cholesterol and CHD risk — the Framingham study. Am J Med 62:707–714
Holme I (1982) On the separation of the intervention effects of diet and antismoking advice on the incidence of major coronary events in coronary high risk men. The Oslo study. J Oslo City Hosp 32:31–54
Jacobs DR (1985) HDL cholesterol and coronary heart disease, cardio-vascular disease and all cause mortality. Circulation 72 (III): 185
Levy RI, Brensike JF, Epstein SE et al. (1984) The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary disease: results of the NHLBI type II coronary intervention study. Circulation 69:325–337
LRC Program (1984) The lipid research clinics coronary primary prevention trial results. II. J Am Med Assoc 251:365–374
Maciejko JJ, Holmes DR, Kottke BA et al. (1983) Apolipoprotein AI as a marker of angiographically assessed coronary-artery disease. N Engl J Med 309:385–389
MRFIT Research Group (1986) Relationship between baseline risk factors and coronary heart disease and total mortality in the multiple risk factor intervention trial. Prev Med 15:254–273
Muuronen A, Kaste M, Nikkilä E, Tolppanen E-M (1985) Mortality from ischaemic heart disease among patients using anticonvulsant drugs: a case-control study. Br Med J 291:1481–1483
Nikkilä E, Viikinkoski P, Valle M, Frick MH (1984) Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia. Br Med J 289:220–223
Ordovas JM, Schaefer EJ, Salem D et al. (1986) Apolipoprotein AI gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. N Engl J Med 314:671–677
Reed D, Yano K, Kagan A (1986) Lipids and lipoproteins as predictors of coronary heart disease, stroke and cancer in the Honolulu heart program. Am J Med 80:871–878
Rudel LL, Leathers CW, Bond MG, Bullock BC (1981) Dietary ethanol-induced modifications in hyperlipoproteinemia and atherosclerosis in nonhuman primates. Arteriosclerosis 1:144–155
Streja D, Steiner G, Kwiterovich PO (1978) Plasma high density lipoproteins and ischemic heart disease. Studies in large kindred with familial hypercholesterolemia. Ann Int Med 89:871–880
Vesselinovitch D, Wissler RW, Fisher-Dzoga K et al. (1974) Regression of atherosclerosis in rabbits. Atherosclerosis 19:259–275
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Miller, N.E. (1987). Can We Retard Atherogenesis by Modifying High-Density Lipoprotein Metabolism?. In: Paoletti, R., Kritchevsky, D., Holmes, W.L. (eds) Drugs Affecting Lipid Metabolism. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71702-4_36
Download citation
DOI: https://doi.org/10.1007/978-3-642-71702-4_36
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71704-8
Online ISBN: 978-3-642-71702-4
eBook Packages: Springer Book Archive